Interim report January 1 - September 30, 2022

Report this content

July-September 2022

Net revenue for the period was SEK 237.0 million (105.6), an increase of 124.5 %. Organic growth was 27.2 %.

Orders received for the period was SEK 268.4 million (107.1), an increase of 150.7 %. Organic growth was 20.6 %.

Adjusted EBITDA for the period was SEK 36.0 million (14.5)

EBITDA for the period was SEK 39.2 million (13.3)

Profit/loss for the period was SEK 33.9 million (-1.6)

Earnings per share for the period amounted to SEK 0.19 (-0.01)

Cash flow from Operations for the period was SEK 20.8 million

January-September 2022

Net revenue for the period was SEK 631.3 million (310.9), an increase of 103.0 %. Organic growth was 11.4 %.

Orders received for the period was SEK 660.1 million (327.4), an increase of 101.6 %. Organic growth was 10.6 %.

Adjusted EBITDA for the period was SEK 89.0 million (38.0)

EBITDA for the period was SEK 94.7 million (37.9)

Profit/loss for the period was SEK 53.0 million (1.0)

Earnings per share for the period amounted to SEK 0.30 (0.01)

Cash flow from Operations for the period was SEK 42.9 million

CEO’s comments

A strong quarter of robust organic growth and improved margins

Q3 was characterized by strong organic growth and improved margins. Organic net revenue growth amounted to 27.2 %. This growth was primarily driven by increased demand from our customers, a reduction in supply chain disruptions, and a favorable currency trend. Orders received remained strong, increasing organically by 20.6 % during the quarter.

Adjusted EBITDA improved compared with Q3 2021, amounting to SEK 36.0 million (14.5). We have systematically worked on improving our margins and, despite a challenging environment characterized by inflation and price increases, we have been able to strengthen our EBITDA margin by passing on increased costs to our customers. Currency tailwinds and acquisitions have also contributed to the stronger margins. The Group’s adjusted EBITDA margin increased to 15.2 % (13.7) during the quarter.

Our underlying markets are continuing to show strength. Activity in our Healthcare business unit remains high, and the equipment used in day-to-day care see high consumption, especially in the U.S. market, which now accounts for more than 50 % of our business and revenue. With regard to hospital equipment that requires investment decisions, we may see a certain amount of caution at the moment. However, capital goods for hospitals in the United States actually represent less than 5 % of the Group’s total revenue.

Investment in research facilities and related equipment remains at a good level. Many projects that did slow down during the pandemic are now being completed, and this is also driving the sale of instruments and consumables used in research. We are seeing a sharp increase in clean room projects in the Middle East as these investments are often linked to the USD and the oil price. We are currently completing a large clean room project in Egypt that will be used in the production of mRNA vaccines.

The Group’s order book is now at historically high levels. This situation, combined with healthy organic growth in orders received, means that we have good visibility with the expectation of further strong quarters.

We are continuing to work actively to identify complementary acquisitions. The selection of companies that fit into one of our two business units is good at present. Yet we can also see that there was a slight multiple contraction in private M&A deals during Q3, not least in Sweden. Our priority growth markets are the Nordic region, the United States, and the United Kingdom. These are markets with a strong focus on high-quality research and healthcare, and which also have different but well-functioning healthcare systems. The Group’s net interest-bearing liabilities are now below our long-term target of 3.0 times pro forma EBITDA. At the end of Q3 it was 2.8 times pro forma EBITDA. This means that our ability to continue making complementary acquisitions remains.

Rikard Akhtarzand, CEO, ADDvise Group AB (publ)

For further information, please contact:

Rikard Akhtarzand, CEO

+46 (0)8-128 766 08

Sebastian Robson, CFO

+46 (0)70-441 84 48

ADDvise Group AB (publ), Grev Turegatan 30, SE-114 38 Stockholm, Sweden

Important information:

This information is information that ADDvise Group AB is required to disclose under the EU Market Abuse Regulation and pursuant to the Swedish Securities Market Act. The information was submitted for publication on October 28, 2022 at 08:15 CEST.

ADDvise’s financial reports are available on ADDvise’s website,

The interim report is published in Swedish and English. The Swedish version represents the original.

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The Group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expanding the business – both geographically and product-wise. ADDvise Group’s shares are listed on Nasdaq First North Premier Growth Market and Mangold Fondkommission AB, +46 8 503 015 50,, is the Company's Certified Adviser. Additional information is available at


Documents & Links